CRSP Analyst Estimates: Price Targets, Revenue, Net Income, and EBIT Forecast - CRISPR Therapeutics AG - Alpha Spread

First Time Loading...

Watchlist Manager

Watchlist

Price: 53.55 USD 0.49%

Updated:

Section:

Wall Street
Price Targets

Wall Street analysts forecast CRSP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CRSP is 87.59 USD with a low forecast of 30.3 USD and a high forecast of 208.95 USD.

CRSP Lowest Forecast

Wall Street Target

CRSP Average Forecast

Wall Street Target

CRSP Highest Forecast

Wall Street Target

43% Downside

64% Upside

290% Upside

The latest public price target was made on May 9, 2024 by Jack Allen from Robert W. Baird , who expects CRSP stock to drop by 3% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst	Price Target	Date	Article
Jack Allen Robert W. Baird	52 USD Downside 3%	1 day ago May 9, 2024	CRISPR Therapeutics (CRSP) PT Raised to $52 at Baird StreetInsider

Price Target	52 USD
Upside/Downside	3%

GI Innovation Inc

82% Upside

HOOKIPA Pharma Inc

452% Upside

Alvotech SA

24% Upside

Yantai Dongcheng Biochemicals Co Ltd

46% Upside

GI Innovation Inc

82% Upside

HOOKIPA Pharma Inc

452% Upside

Alvotech SA

24% Upside

Yantai Dongcheng Biochemicals Co Ltd

46% Upside

Hans Biomed Corp

180% Upside

Moderna Inc

15% Upside

Suzhou Zelgen Biopharmaceuticals Co Ltd

7% Upside

Bio-FD&C Co Ltd

33% Upside

Revenue
Forecast

For the last 8 years the compound annual growth rate for CRISPR Therapeutics AG's revenue is 156%. The projected CAGR for the next 3 years is 38%.

156%

38%

9%

What are analyst estimates?

Operating Income
Forecast

N/A

N/A

-1%

What are analyst estimates?

Net Income
Forecast

N/A

N/A

-37%

What are analyst estimates?

See Also

Relative Valuation

Wall Street Estimates

Profitability Analysis

Solvency Analysis

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

According to Wall Street analysts, the average 1-year price target for CRSP is 87.59 USD with a low forecast of 30.3 USD and a high forecast of 208.95 USD.

For the last 8 years the compound annual growth rate for CRISPR Therapeutics AG's revenue is 156%. The projected CAGR for the next 3 years is 38%.

Join more than 135,900+ value investors using Alpha Spread

Create a free account

or see our plans & pricing

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

What is Intrinsic Value? Help Center Contact Us

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.